Refine by
Hematology Articles & Analysis: Older
172 news found
Utilizing a range of specialized animal-specific hematology analyzers, biochemical analyzers, small animal PET/MRI imaging systems, and other instruments, Ace Therapeutics will conduct modeling, drug administration, sampling, and testing of physiological and biochemical indices in common laboratory animals for clients. ...
Groups listed by CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer treatment · Are taking medications that ...
Similarly, clinical labs worldwide rely on Advanced Instruments’ innovative solutions for delivery of accurate and timely patient results in their clinical chemistry, microbiology, and hematology labs. About Xtalks Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and ...
Groups listed by the CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer treatment · Are taking medications that ...
The full results were presented at an oral presentation during the ASCO GU Congress 2023 and simultaneously published in the Journal of Clinical Oncology.1 “These latest findings from the ARASENS trial continue to reinforce the strong efficacy and favorable safety profile of darolutamide in mHSPC,” said Maha Hussain, M.D., Genevieve Teuton Professor of Medicine in the Division of ...
ByBayer AG
It was recognized 2006 as a national reference center for France under the stewardship of Paul Coppo (Hematology department, Saint-Antoine Hospital and Sorbonne-University) in Paris. ...
Viral vectors can be used for the treatment of various diseases such as: muscular, metabolic, hematologic, ophthalmologic, and infectious diseases as well as different types of cancer. ...
ByNuvonis
Dr Ghobrial was recently awarded the William Dameshek Prize, an award that is given annually by the American Society of Hematology (ASH) for outstanding contributions in hematology. MM accounts for 10% of hematological malignancies and has a current worldwide incidence level of 160,0002. ...
Most of the adverse events (AEs), including nausea and musculoskeletal pain were grade 1 and 2. No hematological safety signal was observed and none of the patients in either of the two treatment arms had sinus bradycardia. ...
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will ...
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug ...
Galapagos NV (Euronext & NASDAQ: GLPG) and CellPoint (a Galapagos company) today presented encouraging initial data from the ongoing ATALANTA-1 Phase 1/2 study with GLPG5101 at the 64th Annual American Society of Hematology (ASH) Congress taking place in New Orleans, Louisiana, from 10-13 December. ...
Results from the study were featured in a poster presentation as Abstract 2171 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on December 10, 2022 and have been published online at Blood®. ...
The findings were presented during two oral sessions at the 64th American Society of Hematology (ASH 2022) Annual Meeting and Exposition in New Orleans, Louisiana. ...
Meanwhile, a large number of potential candidate peptides targeting the metabolic, cardiovascular, central and peripheral nervous systems, as well as endocrine, immune, hematological, allergic, and other malignant diseases, are in early-stage research or clinical trials. ...
A low percentage of patients received an antiemetic; 8.0% on elacestrant, 3.7% on fulvestrant, and 10.3% on AI, respectively. No hematological safety signal was observed and none of the patients in either of the two treatment arms had sinus bradycardia. ...
PT Location: New York The JMP Securities Hematology and Oncology Summit Format: Fireside Chat Date: Tuesday, December 6, 2022 Time: 3:40 p.m. ...
About Antengene Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, driven by its vision ...
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which demonstrated an ORR of 16.7% in the 45 mg ...
IN8bio plans to present additional data for INB-100 at the upcoming 64th American Society of Hematology (ASH) Annual Meeting to take place December 10-13 in New Orleans, Louisiana. ...